bluebird bio to Present at Wedbush PacGrow Healthcare Conference
August 09 2017 - 8:00AM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company
committed to developing potentially transformative gene therapies
for severe genetic diseases and T cell-based immunotherapies for
cancer, today announced that members of the management team will
present at the 2017 Wedbush PacGrow Healthcare Conference on
Tuesday, August 15 at 3:05 pm ET. The conference is being held
August 15-16, 2017 at the Le Parker Meridien in New York.
To access the live webcast of bluebird bio’s presentation,
please visit the “Calendar of Events” page within the Investors and
Media section of the bluebird bio website at
http://investor.bluebirdbio.com. Replays of the webcast will be
available on the bluebird bio website for 90 days following the
conference.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
regarding the Company’s product candidates and research programs.
Any forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing
clinical trials, the risk of cessation or delay of any of the
ongoing or planned clinical studies and/or our development of our
product candidates, the risk of a delay in the enrollment of
patients in our clinical studies, risks that the current or planned
clinical trials of the LentiGlobin drug product will be
insufficient to support regulatory submissions or marketing
approval in the United States and European Union, the risk that our
collaborations, including the collaboration with Celgene, will not
continue or will not be successful, and the risk that any one or
more of our product candidates will not be successfully developed,
approved or commercialized. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in our annual report on Form 10-K and our most recent quarterly
report on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and bluebird bio undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170809005188/en/
bluebird bio, Inc.Investors:Manisha Pai,
617-245-2107mpai@bluebirdbio.comorMedia:Elizabeth Pingpank,
617-914-8736epingpank@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024